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Background. Ocular bartonellosis can present in various ways, with variable visual outcome. There is limited data on ocular
bartonellosis in Malaysia. Objective. We aim to describe the clinical presentation and visual outcome of ocular bartonellosis in
Malaysia.Materials and Methods.This was a retrospective review of patients treated for ocular bartonellosis in two ophthalmology
centers inMalaysia between January 2013 and December 2015.The diagnosis was based on clinical features, supported by a positive
Bartonella spp. serology. Results. Of the 19 patients in our series, females were predominant (63.2%). The mean age was 29.3 years.
The majority (63.2%) had unilateral involvement. Five patients (26.3%) had a history of contact with cats. Neuroretinitis was the
most common presentation (62.5%). Azithromycin was the antibiotic of choice (42.1%). Concurrent systemic corticosteroids were
used in approximately 60% of cases. The presenting visual acuity was worse than 6/18 in approximately 60% of eyes; on final
review, 76.9% of eyes had a visual acuity better than 6/18. Conclusion. Ocular bartonellosis tends to present with neuroretinitis.
Azithromycin is a viable option for treatment. Systemic corticosteroids may be considered in those with poor visual acuity on
presentation.
1. Introduction
Cat-scratch disease is caused by the Gram-negative, intra-
cellular bacteria Bartonella henselae. When ocular involve-
ment is present, the disease is termed “ocular bartonellosis.”
The spectrum of ocular bartonellosis manifestation is wide,
ranging from neuroretinitis to Parinaud’s oculoglandular
syndrome, which is an unusual syndrome characterized
by granulomas in the eye, preauricular lymphadenopathy,
and positive skin test to Bartonella spp. antigens [1–4]. In
Malaysia, the data on cat-scratch disease, particularly ocular
bartonellosis, is limited [5]. We aim to describe the clinical
manifestations and visual outcome of ocular bartonellosis
in Malaysia. We also outline the relevant investigations for
this condition and discuss the management of this zoonotic
disease.
2. Materials and Methods
We performed a retrospective review of medical records of
patients with ocular bartonellosis treated in two ophthalmol-
ogy centers in Malaysia, between 2013 and 2015. The conduct
of the study followed the tenets outlined in the Declaration of
Helsinki.
Selection criteria for this study were a diagnosis of ocular
bartonellosis based on history of exposure to cats, ocular
examination findings, and a single positive serology for
Bartonella spp. Any two of these were sufficient to make
the diagnosis. Patients suspected of ocular bartonellosis
were also investigated for other possible infective causes
(tuberculosis, syphilis). Serological tests were all performed
via immunofluorescence assay (IFA) in the Bacteriology
Unit, Institute for Medical Research, Ministry of Health
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Table 1: Patient demographic profile.
Demographic data 𝑛 (%)
Age in year (mean, SD) 29.3, 13.2
Race
Malay 19 (100.0)
Sex
Male 7 (36.8)
Female 12 (63.2)
Cat exposure
No 14 (73.7)
Yes (contact or scratch) 5 (26.3)
Systemic symptoms
No 8 (42.1)
Yes 11 (57.9)
Headache 7 (43.8)
Upper respiratory tract infection 2 (12.5)
Fever 6 (37.5)
Lymphadenopathy 1 (6.2)
Malaysia. The cut off value was 1 : 12 for IgM and 1 : 64 for
Ig G using a commercial kit to detect Bartonella henselae
and Bartonella quintana (Vircell IFA Bartonella, Paraque
Tecnologico, Granada, Spain).
Data collected included onset and duration of visual
disturbance, associated systemic symptoms, visual acuity,
optic nerve function, anterior and posterior segment exam-
ination, treatment regime, and visual outcome. The latter
was evaluated based on visual acuity at the last follow-up
visit. Visual acuity was assessedmonocularly, with the patient
seated 6 meters from a Snellen chart. A 6/6 Snellen visual
acuity means the patient can read at 6 meters a letter that
a normal person would be able to read at 6 meters. The
denominator in Snellen visual acuity notation describes the
distance at which a normal individual is able to identify a
certain symbol, while the numerator refers to the distance
required by the patient to identify the same symbol. In this
study, a visual acuity of 6/18 or better was considered good,
while visual acuity worse than 6/18 was considered poor.
Follow-up was until completion of the course of antibiotics,
given for a minimum of six weeks.
The data were analyzed using the Statistical Package for
Social Science, version 22.0 (SPSS Inc., Chicago, IL, USA).
The results are presented as frequencies and percentages.
3. Results
A total of 19 patients (26 eyes) with ocular bartonellosis were
diagnosed within the study period. The period of follow-up
ranged from 3 to 68 weeks, with the mean duration of follow-
up being 23.4 weeks. Two patients were lost to follow-up.The
duration of symptoms ranged from 5 days to 1 month prior to
their first consultation at eye clinic.
The demographic and clinical profile of our subjects is
summarized in Table 1. The mean age was 29.3 years. All
were Malay, and most of them were female (63.2%, 𝑛 = 12).
Only 5 (26.3%) patients gave a history of being scratched or
bitten by a cat. The majority (63.2%, 𝑛 = 12) had unilateral
involvement.
The most common ocular complaint was blurring of
vision, with 61.6% (16 eyes) presenting with a visual acuity
worse than 6/18. About one-quarter (7 eyes) had a visual acu-
ity ofworse than 6/60. Approximately 62.5%of eyes presented
with neuroretinitis. Optic disc edema was seen in 42.1% of
patients. One patient presented with features of vasculitis
complicated with central retinal vein occlusion, evidenced
by macular edema, dilated and tortuous vessels, and flame-
shaped hemorrhages. Six patients (31.6%) had signs of uveitis.
Ocular findings on presentation and treatment regimes are
shown for each patient in Table 2. Table 3 shows a summary
of the ocular presentation and results of serological testing.
Approximately 57.9% of patients had prodromal symp-
toms, of which headache was the most common. Less
common symptoms were fever and upper respiratory tract
symptoms. Bartonella spp. Ig G serology was positive in all
patients, while 68.4% (𝑛 = 13) had positive Ig M serology.
Only a single serology test was performed, due to financial
constraints. Hence, disease progression was assessed based
on clinical response. The duration of ocular symptoms did
not vary between patients with positive Ig G and negative Ig
M and those who were positive for both of these.
All patients except two received treatment, which was
initiated within the first week of diagnosis. In the case of the
latter, this was due to spontaneous recovery before treatment
could be initiated. Azithromycin was the most common
antimicrobial agent used for treatment (42.1%). Doxycycline,
ciprofloxacin, ceftazidime, and cotrimoxazole were other
agents used. Approximately 57.9% (𝑛 = 11) received systemic
corticosteroid therapy. Six of these patients were treated with
pulsed intravenous corticosteroid therapy, followed by oral
corticosteroids. The overall final visual acuity was good, with
approximately 76.9% of eyes achieving a good visual outcome
(visual acuity of 6/18 or better).
4. Discussion
Cat-scratch disease, that is, bartonellosis, is a self-limiting
condition in immunocompetent individuals. The spectrum
of systemic involvement in bartonellosis ranges from endo-
carditis to thyroiditis, arthritis, haemolytic anemia, and
glomerulonephritis [6–10].The ocular manifestations of Bar-
tonella spp. infection are likewise myriad and have included
scotomas [11], papillitis, [12] retinal artery occlusions [13],
and even a macular hole [14]. Although systemic cat-scratch
disease primarily affects young patients, ocular bartonellosis
has a broader age distribution [15]. Our mean age of 29.3
years, with a range of 9 to 58 years, is similar to that of Curi
et al. in Brazil [2].
Cats are the main reservoir for Bartonella spp., and the
main vector of cat-scratch disease is the flea Ctenocephalides
felis [16]. Cats are common in Malaysia, both as household
pets and strays. The prevalence of Bartonella henselae in
fleas from healthy cats and dogs has been shown to be
approximately 33%, while among strays, almost a quarter of
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Table 3: Presenting features of ocular bartonellosis.
Parameters 𝑛 (%)
Laterality
Left 8 (42.1)
Right 4 (21.1)
Bilateral 7 (36.8)
Ocular presentation
Anterior uveitis 6 (31.6)
Neuroretinitis 10 (62.5)
Optic disc edema 8 (42.1)
Focal choroiditis 1 (5.3)
Retinal infiltrates 2 (10.5)
Cotton wool spots 1 (5.3)
Retinal hemorrhages 3 (15.8)
Macular edema 1 (5.3)
Vasculitis 2 (10.5)
IFA serology positivity
Ig M 13 (68.4)
Ig G 19 (100.0)
IFA, immunofluorescent assay; Ig, immunoglobulin.
them have been found to be seropositive for the bacterium
[12, 17]. Exposure to cats or a history of cat-scratch or cat
bite is usually present in more than 50% of reported cases
of bartonellosis [2, 18–20]. A recent study among healthy
blood donors in Brazil revealed that cat contact or a history
of tick bite conferred an adjusted odds ratio of Bartonella spp.
bloodstream infection of 3.4 (95% CI 1.1–9.6) and 3.7 (95%CI
1.3–13.4), respectively [21]. Our study results contradict those,
as only approximately one-quarter of our patients had this
history. We thus counsel the reader that although a history
of cat exposure is common, it is not a prerequisite to make
the diagnosis, especially in regions where cats abound [22].
Neuroretinitis in ocular bartonellosis is usually unilateral,
but bilateral presentation has been reported [2, 23–25].
In our study, 63.2% of patients presented with unilateral
involvement. This is similar to the percentage noted by
Kerkhoff et al., who noted that 61.5% of ocular bartonellosis
was unilateral [18]. Nearly all (8 out of 9) patients with
neuroretinitis had unilateral involvement. Meanwhile, all
those with panuveitis (4 patients) had bilateral involvement
[18]. Our results differ from those of Curi et al., who reported
that 13 out of 24 patients (54.2%) presented with bilateral
disease [2].
Neuroretinitis and focal retinochoroiditis are the most
common ocular manifestations of cat-scratch disease [2, 19,
20, 23, 24]. In our series, neuroretinitis remained the most
common presentation, followed by optic disc swelling. This
varies from the findings of Solley et al., who reported that,
in his study of 24 patients, the most common finding was
discrete retinal infiltrates or choroidal lesions, seen in 83% of
patients, followed by optic disc swelling, in 63% of patients
[1]. Curi et al. had similar findings to Solley et al., in which
the most common ocular manifestation was a small area of
retinal infiltrate, which occurred in 11 eyes [1, 2]. In that series,
neuroretinitis occurred in only 6 out of 37 eyes (16.2%) [2].
The seroprevalence of antibodies to Bartonella henselae
varies worldwide, ranging from 3.8% to 50% in various stud-
ies [26–28]. To the best of our knowledge, there is no available
data on the seroprevalence of Bartonella henselae antibodies
in our general population. Elevated immunoglobulin M (Ig
M) or G (Ig G) for Bartonella henselae is suggestive of current
or past infection [29]. However, the sensitivity of an Ig M
assay using IFA has been found to be lower than that of
enzyme immunoassay (EIA) Ig M (50% IFA versus 71.4%
EIA) in patients who fulfilled two or more criteria for cat-
scratch disease [30]. Despite this, IFA remains the only test
of bartonella infection available in our setting. Unfortunately,
the IFA used in our bacteriology unit measures antibodies to
both Bartonella henselae and Bartonella quintana; therefore,
we were unable to differentiate between these Bartonella spp.
infections. Polymerase chain reaction (PCR) is emerging as
an alternative, highly sensitive method of identifying Bar-
tonella spp. in ocular specimens [18, 21]. PCR hybridization
assay has shown 86.4% sensitivity in patients who fulfill two
or more criteria for cat-scratch disease and 100% sensitivity
in patients who fulfill three or more criteria [27]. However,
routine PCR is not readily done in our setting due to high
cost. We foresee the need for better serological diagnostic
tests to guide the diagnosis and treatment of bartonella
infection in our practice.
Generally, cat-scratch disease is a self-limiting disease,
with good visual prognosis, but treatment may hasten
recovery [20, 31]. Early antibiotic treatment may not only
speed recovery, but also improve the final visual outcome
[20]. According to Bass et al., the mean duration of illness
was 2.8 weeks in those with treatment, compared to 14.5
weeks in those without treatment [32]. Rifampicin, gen-
tamicin, cotrimoxazole, ciprofloxacin, and doxycycline have
shown efficacy in the treatment of cat-scratch disease [20].
However, doxycycline is contraindicated in children and
pregnant women. In mild to moderate disease, the use of oral
azithromycin for five-day duration achieves more rapid res-
olution of lymphadenopathy than conservative management
[33]. Azithromycin has become the preferred antimicrobial
of choice in treating ocular bartonellosis in our setting due
to issues with compliance (daily dosing) and its improved
safety profile compared to doxycycline (which is given twice
a day and tends to cause gastrointestinal upset). There is no
prospective study on the efficacy of azithromycin in treating
ocular bartonellosis. However, susceptibility evaluation of
Bartonella henselae against macrolide antibiotics found that
these antibiotics are useful in the treatment of cat-scratch
disease [34].
The role of systemic corticosteroids in the treatment
of cat-scratch disease is still controversial. Isolated case
reports have demonstrated good response to corticosteroids,
especially in cases where the presentation is atypical [35–38].
Only one study of ocular bartonellosis has discussed the role
of corticosteroids, which gave a good outcome when used
in combination with antibiotics, in a series of 14 patients
in Japan [19]. Corticosteroids may help control the degree
of intraocular inflammation and optic neuropathy due to
Journal of Tropical Medicine 5
cat-scratch disease. In our study, systemic corticosteroid
therapy was used in patients who had significantly decreased
visual acuity on presentation. However, we do not believe
that topical corticosteroids play a significant role in the
management of this condition, as their penetration to the
posterior segment of the eye is limited.
Our study has several limitations. First, its retrospective
nature limits the amount of information available. Secondly,
although our data was collected from two institutions, the
demographic and clinical features of this disease may show
a wider global variation than currently reported, due to the
different socioeconomic and bacteriology profile in different
regions.Direct comparisonwith previous literature is also not
possible due to the relatively small numbers of patients in
most studies, as well as differences in study design, including
inclusion criteria and type of serological assay used. Larger
scale studies and standardized diagnostic criteria are required
to consolidate our findings.
5. Conclusion
Ocular bartonellosis tends to present with blurring of vision,
which is associated with prodromal symptoms in more
than half of these cases. The most common ocular signs
are neuroretinitis, papillitis, and uveitis. Azithromycin is a
viable option for treatment. Systemic corticosteroids may be
considered in those with poor visual acuity on presentation.
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